Sonnet BioTherapeutics Holdings, Inc.
CIK: 0001106838
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 100 OVERLOOK CENTER, PRINCETON, NJ, 08540
Mailing Address 100 OVERLOOK CENTER, PRINCETON, NJ, 08540
Phone 609-375-2227
Fiscal Year End 0930
EIN 522102141
Financial Overview
FY2025
-$7.44M
Net Income
$4.10M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 4, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 8-K Current report of material events | December 3, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
Annual Reports
10-K December 16, 2025
- Secured significant funding through multiple offerings of common stock and warrants in late 2023 and throughout 2024.
- Expanded research and development efforts through new and existing collaborations with partners like Alkem, Cellca, The Brink, InvivoGen, ProteoNic, and Navigo Proteins GmbH.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.